ACUTE MYELOGENOUS LEUKEMIA
Clinical trials for ACUTE MYELOGENOUS LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new ACUTE MYELOGENOUS LEUKEMIA trials appear
Sign up with your email to follow new studies for ACUTE MYELOGENOUS LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug targets genetic weakness in Hard-to-Treat blood cancers
Disease control CompletedThis study tests a drug called FT-2102 (olutasidenib) in people with acute myeloid leukemia or myelodysplastic syndrome whose cancers have a specific IDH1 gene mutation. The drug is given alone or combined with standard chemotherapy drugs (azacitidine or cytarabine). The goal is …
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA
Phase: PHASE1, PHASE2 • Sponsor: Forma Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Experimental cell therapy targets Hard-to-Treat leukemia
Disease control CompletedThis early-phase study tested a new cell therapy called LILRB4 STAR-T cells in one person with monocytic leukemia, a type of blood cancer. The goal was to see if the treatment is safe and can reduce cancer cells in the bone marrow. Researchers monitored side effects like cytokine…
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New chemo combo before donor transplant shows promise for leukemia patients
Disease control CompletedThis study tested adding a drug called thiotepa to the usual chemotherapy given before a donor stem cell transplant for people with leukemia. The goal was to see if this stronger mix could help more patients stay cancer-free one year after the transplant. The study included 40 ad…
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug combo may make bone marrow transplants safer for blood cancer patients
Disease control CompletedThis early-phase trial tested replacing the standard drug cyclophosphamide with bendamustine after a half-matched bone marrow transplant in 50 patients with various blood cancers. The goal was to see if this change could reduce side effects like graft-versus-host disease while st…
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA
Phase: PHASE1 • Sponsor: University of Arizona • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for young AML patients: epigenetic drugs plus chemotherapy show promise
Disease control CompletedThis early-phase study tested whether adding two drugs (decitabine and vorinostat) before and during standard chemotherapy (FLAG) is safe for children and young adults up to age 25 with acute myeloid leukemia (AML) that has come back or not responded to treatment. The goal was to…
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA
Phase: PHASE1 • Sponsor: Therapeutic Advances in Childhood Leukemia Consortium • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Can we predict who bounces back after a bone marrow transplant?
Knowledge-focused CompletedThis study looked at 126 people aged 60 and older who had a bone marrow transplant for blood cancers like leukemia or lymphoma. Researchers measured physical abilities, mental health, and stress levels before and after transplant to find traits that help people recover better. Th…
Matched conditions: ACUTE MYELOGENOUS LEUKEMIA
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC